

17 June 2011

AquaBounty Technologies
(“AquaBounty” or “the Company”)

Company Response to Congressional Bill

AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, notes the comments in the media regarding the recent event in the US House of Representatives and provides the following clarification.

On 15 June 2011, an amendment to the Agricultural Appropriations Bill was introduced by a representative from Alaska to prohibit the Food and Drug Administration (FDA) from utilizing any of the appropriated funds for the purpose of approving "genetically engineered salmon." At the time the amendment was introduced and approved by voice-vote, there were fewer than ten members (out of a total of 435) of the House of Representatives in attendance. This amendment does not represent a broad consensus of opinion by US lawmakers, and is viewed by many as subverting the authority of the FDA and undermining science-based regulatory policy.

The management of the Company believes that it is unlikely that this provision will be included in any eventual final law passed by the House and the Senate. Leadership in both the House and Senate have historically rejected attempts to subvert the science based regulatory policy of the FDA. AquaBounty is in dialogue with the FDA and remains confident that they will complete their administrative process and approve the Company's pending New Animal Drug Application for AquAdvantage[®] Salmon.

Enquiries:

AquaBounty Technologies
David Frank, CFO

+1 781 899 7755

Nomura Code Securities
Richard Potts, Giles Balleny

+44 (0)20 7776 1200

Corfin Public Relations
Harry Chathli, Claire Norbury

+44 (0)20 7596 2860